Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc

NNASDAQ:BRNS
0.74
USD
-0.02
(-2.49%)
-1.02EPS
26.96MMarket Cap

Total Valuation

USD

As of June 30, 2026, Barinthus Biotherapeutics plc carries a market capitalization of 26.96M, placing it among publicly traded companies globally. Its enterprise value stands at -21.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap26.96M
Enterprise Value-21.98M

Important Dates

Barinthus Biotherapeutics plc's next confirmed earnings release is scheduled for November 5, 2026.

Earnings Date11/5/2026

Share Statistics

As of June 30, 2026, Barinthus Biotherapeutics plc has 40.85M shares outstanding.

Shares Outstanding40.85M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio0.47
P/TBV Ratio0.61
P/FCF Ratio-1.02
P/OCF Ratio-1.02

Financial Position

As of June 30, 2026, Barinthus Biotherapeutics plc maintains a current ratio of 5.54, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.02, indicating elevated leverage, while an interest coverage ratio of -759.23 demonstrates limited ability to service its debt obligations.

Current Ratio5.54
Quick Ratio5.33
Debt / Equity18.02
Debt / EBITDA-0.26
Interest Coverage-759.23

Financial Efficiency

Over the twelve months ended June 30, 2026, Barinthus Biotherapeutics plc posted a negative return on equity (ROE) of -52.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.50, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 36.75, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-52.39
Return on Assets (ROA)-39.50
Employee Count36.75

Taxes

USD

Over the twelve months ended June 30, 2026, Barinthus Biotherapeutics plc recorded an income tax benefit of -167,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -41.97M and -41.77M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-167,000.00

Stock Price Statistics

USD

As of the close on September 8, 2026, Barinthus Biotherapeutics plc's stock has declined approximately 39.09% over the past 52 weeks. The 50-day moving average sits at 0.63, while the 200-day moving average is 0.66.

52-Week Price Change-39.09%
50-Day Moving Average0.63
200-Day Moving Average0.66

Income Statement

USD

Over the twelve months ended June 30, 2026, Barinthus Biotherapeutics plc generated - - in revenue and converted that into -41.77M in net income, yielding earnings per share of -1.02. EBITDA reached -40.24M, while operating income came in at -38.51M.

Operating Income-38.51M
Pretax Income-41.97M
Net Income-41.77M
EBITDA-40.24M
EBIT-43.72M
Earnings Per Share (EPS)-1.02

Balance Sheet

USD

As of June 30, 2026, Barinthus Biotherapeutics plc holds 59.30M in cash and equivalents against 10.30M in total debt, resulting in a net debt position of -59.29M. Total book value stands at 57.07M, with working capital of 51.85M providing operational flexibility.

Cash & Cash Equivalents59.30M
Total Debt10.30M
Net Debt-59.29M
Equity (Book Value)57.07M
Book Value Per Share1.40
Working Capital51.85M

Cash Flow

USD

Barinthus Biotherapeutics plc produced -26.42M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -26.42M - equivalent to -0.65 per share.

Operating Cash Flow-26.42M
Free Cash Flow-26.42M
FCF Per Share-0.65

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -98.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Barinthus Biotherapeutics plc shareholders.

FCF Yield-98.13

Scores

As of June 30, 2026, Barinthus Biotherapeutics plc has an Altman Z-Score of -6.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-6.80